Sanofi Multiple Sclerosis Drug Gets EU Approval

The EU approval of Sanofi's Cenrifki marks a significant milestone for the company's efforts in the multiple sclerosis treatment market, especially as it faces rejection in the U.S. This development could influence global access to innovative MS therapies and impact competitive dynamics within the pharmaceutical industry.

• Cenrifki is now approved for use in the EU, expanding Sanofi's market reach.
• The drug's rejection by U.S. regulators highlights differing regulatory standards and approval processes.
• This approval may lead to increased competition and innovation in MS treatments globally.